<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04200586</url>
  </required_header>
  <id_info>
    <org_study_id>Version no.3</org_study_id>
    <nct_id>NCT04200586</nct_id>
  </id_info>
  <brief_title>The Effects of SGLTi on Diabetic Cardiomyopathy</brief_title>
  <acronym>SGLTi</acronym>
  <official_title>The Effects of SGLT Inhibition on Diabetic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic cardiomyopathy is associated with significant morbidity and mortality. It is&#xD;
      considered as a cardiac muscle disorder secondary to diabetes mellitus (DM). Certain studies&#xD;
      show the clinical benefit of SGLT-s inhibitors on reducing cardiovascular outcomes amongst&#xD;
      patients with type II DM that go beyond the correction of hyperglycemic perse. Thus an&#xD;
      observational imaging study is proposed to identify mechanistic insights of the drug group&#xD;
      over cardiovascular events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic cardiomyopathy is defined as ventricular dysfunction in diabetic patients in the&#xD;
      absence of coronary artery disease and hypertension. It is considered as a cardiac muscle&#xD;
      disorder due to the metabolic consequences of DM characterized by left ventricular&#xD;
      hypertrophy, left ventricular diastolic dysfunction (in the early stage), and/or systolic&#xD;
      dysfunction. To date, there is no specific treatment proven effective for the condition due&#xD;
      to the incomplete understanding of the pathogenesis.&#xD;
&#xD;
      Recent studies however prove the efficacy of SGLT-2 inhibitors on reducing the primary&#xD;
      composite end point of cardiovascular outcomes including hospitalization for heart failure,&#xD;
      cardiovascular death, and all-cause death amongst patients with type II DM. Such clinical&#xD;
      benefit is apparently mainly stemmed from the reduction in heart failure related mortality&#xD;
      and sudden cardiac death rather than the macro-vascular events such as myocardial infarct and&#xD;
      stroke, suggesting addition benefits going beyond the correction of hyperglycemia perse.&#xD;
      These studies thus raise the possibility that the drug may have direct effects on the&#xD;
      myocardium that conferring the clinical benefit not related the modification of traditional&#xD;
      risk factors such as glycemic control, lipid, blood pressure, and obesity.&#xD;
&#xD;
      A single-arm, observational cardiac magnetic resonance imaging study is proposed in type II&#xD;
      diabetic patients before and 2 months after initiation of dapagliflozin. The aim is to&#xD;
      identify mechanistic insights leading to the unexpected clinical benefit of SGLT inhibition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 9, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 4, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single-arm, observational</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in myocardial perfusion reserve index</measure>
    <time_frame>8-12 weeks</time_frame>
    <description>Change in myocardial perfusion reserve index calculated from cardiac MRI</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type2 Diabetes</condition>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground.</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  type 2 diabetes&#xD;
&#xD;
          -  40-90 years old&#xD;
&#xD;
          -  HbA1c &gt;= 6.5%&#xD;
&#xD;
          -  history of heart failure with reduced ejection fraction&#xD;
&#xD;
          -  indications for SGLT inhibition on clinical ground&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  angina pectoris or chest discomfort&#xD;
&#xD;
          -  prior coronary artery bypass grafts&#xD;
&#xD;
          -  coronary artery stenting within 6 months of study enrolment&#xD;
&#xD;
          -  pervious myocardial infarct&#xD;
&#xD;
          -  any contraindication for stress CMR testing&#xD;
&#xD;
          -  renal impairment with eGFR &lt;45ml/min/1.73m2&#xD;
&#xD;
          -  limited life expectancy &lt;5 years, for example due to pulmonary disease, cancer or&#xD;
&#xD;
          -  significant hepatic failure&#xD;
&#xD;
          -  contraindication to dapagliflozin or other SGLT2 inhibitors&#xD;
&#xD;
          -  unable to take dapagliflozin&#xD;
&#xD;
          -  patients currently on and SGLT2 inhibitor&#xD;
&#xD;
          -  planned need for concomitant cardiac surgery or coronary intervention&#xD;
&#xD;
          -  refusal or inability to sign an informed consent&#xD;
&#xD;
          -  potential for on-compliance towards the requirements in the trial protocol (especially&#xD;
             the medical treatment) or follow-up visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Chung-Wah SIU, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Chung-Wah David SIU</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Diabetic Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

